Procalcitonin as a biomarker of good prognosis for patients in exacerbation of chronic obstructive pulmonary disease.
Procalcitonin as a biomarker of good prognosis for patients in exacerbation of chronic obstructive pulmonary disease.
DOI:
https://doi.org/10.51473/rcmos.v1i1.2026.2046Keywords:
Pulmonary disease; Procalcitonin; Antibiotic resistance; Medicine.Abstract
Chronic Obstructive Pulmonary Disease (COPD) is a pulmonary condition characterized by persistent airflow limitation, usually associated with smoking, resulting from an abnormal inflammatory response of the airways to the inhalation of harmful particles. COPD exacerbations consist of episodes of acute respiratory symptoms and are associated with increased hospitalizations, deterioration of functional capacity, increased mortality, and reduced quality of life. In this context, procalcitonin (PCT), a biomarker derived from calcitonin, has been investigated as an auxiliary tool to differentiate between infectious and non-infectious exacerbations, in addition to its potential prognostic value. A bibliographic review was conducted using the PubMed, SciELO, and Cochrane databases, including publications from 2020 to 2025, and using the descriptors “pulmonary disease,” “Antibiotic Resistance,” “Procalcitonin,” and “Medicine.” The analyzed studies demonstrated that antibiotic therapy guided by serum PCT levels is associated with a reduction in both antibiotic use and duration, without compromising clinical outcomes, in addition to a lower incidence of adverse effects and a contribution to combating bacterial resistance. Furthermore, elevated PCT levels were associated with greater exacerbation severity, longer hospital stays, and worse clinical prognosis. Therefore, it is suggested that PCT represents a relevant biomarker in the management of COPD exacerbations, assisting both therapeutic decision-making and prognostic assessment, and promoting safer and more individualized patient care.
Downloads
References
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2025 report. [S.l.: s.n.], 2025.
GUO-PARKE, HONG et al. Mechanisms of virus-induced airway immunity dysfunction in the pathogenesis of COPD disease, progression, and exacerbation. Frontiers in Immunology, v. 11, p. 1205, 2020. DOI: https://doi.org/10.3389/fimmu.2020.01205
HOULT, G. et al. Biomarkers to guide the use of antibiotics for acute exacerbations of COPD (AECOPD): a systematic review and meta-analysis. BMC Pulmonary Medicine, v. 22, n. 1, p. 194, 2022. DOI: https://doi.org/10.1186/s12890-022-01958-4
HUEMER, M. et al. Antibiotic resistance and persistence—implications for human health and treatment perspectives. EMBO Reports, v. 21, n. 12, p. e51034, 2020. DOI: https://doi.org/10.15252/embr.202051034
JANSSEN, R. et al. Emphysema: looking beyond alpha-1 antitrypsin deficiency. Expert Review of Respiratory Medicine, v. 13, n. 4, p. 381–397, 2019. DOI: https://doi.org/10.1080/17476348.2019.1580575
LIN, S.-H. et al. Procalcitonin kinetics to guide sequential invasive–noninvasive mechanical ventilation weaning in patients with acute exacerbation of chronic obstructive pulmonary disease and respiratory failure: procalcitonin’s adjunct role. Libyan Journal of Medicine, v. 16, n. 1, 2021. DOI: https://doi.org/10.1080/19932820.2021.1961382
MARUNA, P.; NEDELNÍKOVÁ, K.; GÜRLICH, R. Physiology and genetics of procalcitonin. Physiological Research, v. 49, supl. 1, p. S57–S61, 2000.
MEDINA, V.; MORANTE, M. M.; FERRER, J. L. Valor diagnóstico y pronóstico de la procalcitonina en pacientes con sepsis hospitalizados en el Centro Médico Docente La Trinidad. Revista Científica CMDLT, Caracas, v. 16, n. 1, e-211158, 2022. DOI: https://doi.org/10.55361/cmdlt.v16i1.158
NEGEWO, N. A.; GIBSON, P. G.; MCDONALD, V. M. COPD and its comorbidities: impact, measurement and mechanisms. Respirology, v. 20, n. 8, p. 1160–1171, 2015. DOI: https://doi.org/10.1111/resp.12642
QIYUAN, P. et al. Prognostic value of procalcitonin in acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. PLoS One, v. 19, n. 12, e0312099, 2024. DOI: https://doi.org/10.1371/journal.pone.0312099
SCHUETZ, P. How to best use procalcitonin to diagnose infections and manage antibiotic treatment. Clinical Chemistry and Laboratory Medicine, v. 61, n. 5, p. 822–828, 2023. DOI: https://doi.org/10.1515/cclm-2022-1072
SIVAPALAN, P. et al. Individualised treatment of COPD exacerbations using biomarkers. Ugeskrift for Laeger, v. 186, n. 14, p. V09230560–V09230560, 2024. DOI: https://doi.org/10.61409/V09230560
VOGELMEIER, C. F. et al. Goals of COPD treatment: focus on symptoms and exacerbations. Respiratory Medicine, v. 166, p. 105938, 2020. DOI: https://doi.org/10.1016/j.rmed.2020.105938
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 Gabriela Theodoro Tórtola, Eloisa Maria Gatti Regueiro (Autor)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This means you are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The use of this material is conditioned upon proper attribution to the original author(s), providing a link to the license, and indicating if changes were made. The license does not require permission from the author or the publisher as long as these conditions are met.
The Creative Commons license logo is displayed permanently in the footer of the journal.
The copyright of the manuscript can be retained by the authors without restrictions and can be requested at any time, even after publication in the journal.
How to Cite
